



Statement of Standalone Audited Financial Results for the Quarter and Year Ended 31.03.2020

Rs. in lakhs

Particulars	Standalone			12 Months	12 Months	
	Quarter Ended			Year Ended	Year Ended	
	31.03.2020	31.03.2019	31.12.2019	31.03.2020	31.03.2019	
	Audited	Audited	Unaudited	Audited	Audited	
1	Income from operations					
a	Gross Sales/Revenue from Operations	2951.75	3840.22	4201.04	15856.78	16682.56
b	Other Operating Income	0.00	0.00	0.00	0.00	0.00
	Total Income from operations	2951.75	3840.22	4201.04	15856.78	16682.56
2	Other Income	76.04	87.95	65.08	252.62	142.90
3	Total Income [1+2]	3027.79	3928.17	4266.12	16109.40	16825.46
4	Expenses					
a	Cost of materials consumed	505.01	746.34	1244.12	3678.48	3878.66
b	Purchases of stock-in-trade	343.96	539.39	535.02	1815.19	1464.08
c	Changes in inventories of finished goods, work in progress and Stock in trade	-66.62	101.19	-380.60	124.99	1941.82
d	Employee benefits expenses	1014.37	1059.88	1461.64	5037.42	4661.10
e	Finance Cost	14.71	27.31	10.12	51.41	74.55
f	Depreciation and amortisation expense	31.70	28.13	25.95	112.98	101.58
g	Other expenses	1032.68	1052.23	1084.46	4347.45	3803.39
	Total expenses	2875.81	3554.47	3980.71	15167.92	15925.18
5	Profit before exceptional items and taxes (3-4)	151.98	373.70	285.41	941.48	900.28
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00
7	Profit before tax [5-6]	151.98	373.70	285.41	941.48	900.28
8	Tax expense	-3.50	76.24	57.09	154.40	178.67
9	Net Profit for the period [7-8]	155.48	297.46	228.32	787.08	721.61
10	Other Comprehensive Income					
A	(i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00
11	Total Other Comprehensive Income [A(i) + A(ii)]	0.00	0.00	0.00	0.00	0.00
12	Total Comprehensive Income [9+11]	155.48	297.46	228.32	787.08	721.61
13	Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90
14	Earnings Per Share (before and after extraordinary items)					
	(of Rs 5/- each)					
a.	Basic (Rs.)	0.59	1.14	0.87	3.00	2.75
b.	Diluted (Rs.)	0.59	1.14	0.87	3.00	2.75



Statement of Assets and Liabilities		
Particulars	As on 31.03.2020	As on 31.03.2019
ASSETS		
1 Non-current assets		
(a) Property , Plant and Equipment	2206.02	2161.39
(b) Capital Work-in-Progress	190.34	189.15
(c) Goodwill	3.00	3.00
(d) Intangible assets under development	234.53	206.27
(e) Financial assets		
(i) Investments	1138.68	0.05
(f) Other non-current assets	1431.91	1262.72
Total non-current assets	5204.48	3822.58
2 Current assets		
(a) Inventories	2932.50	3269.26
(b) Financial assets		
(i) Trade receivables	2145.34	2075.02
(ii) Cash and Cash equivalents	27.75	35.70
(iii) Bank balances other than (ii) above	3779.67	3817.76
(c) Other current assets	605.75	558.09
Total current assets	9491.01	9755.83
TOTAL ASSETS	14695.49	13578.41
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share Capital	1309.90	1309.90
(b) Other Equity		
(i) Reserves & Surplus	9793.49	9137.41
Total Equity	11103.39	10447.31
LIABILITIES		
1 Non-current liabilities		
(a) Deferred tax liabilities (Net)	309.16	311.91
(b) Non current borrowings		
Non-current liabilities	309.16	311.91
2 Current Liabilities		
(a) Financial Liabilities		
(i) Trade payables	1170.93	1186.04
(II) Short term borrowings	466.48	378.54
(b) Other current liabilities	815.56	559.97
(c) Provision for tax	829.97	694.64
Total current liabilities	3282.94	2819.19
Total Liabilities	3592.10	3131.10
TOTAL - EQUITY AND LIABILITIES	14695.49	13578.41



NOTES:

1. The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on July 29, 2020. The statutory auditors have expressed an unmodified opinion on the aforesaid results,

2. In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.

3. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.

4. The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

5. The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.

6. The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. Businesses are being forced to cease or limit their operations for long or indefinite period of time. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses worldwide, resulting in an economic slowdown. COVID-19 is significantly impacting business operation of the companies, by way of interruption in production, supply chain disruption, unavailability of personnel, closure / lock down of production facilities etc. On 24th March 2020, the Government of India ordered a nationwide lockdown for 21 days which further got extended till 3rd May 2020 to prevent community spread of COVID-19 in India resulting in significant reduction in economic activities.

7. Provision for taxation includes provision for current tax.

8. The Board of Directors has proposed a dividend of Rs 0.50 per Equity Shares of Rs 5/- each.

9. Figures for the quarter ended 31st March 2020 are balancing figures between the audited figures in respect of full financial year ended 31st March 2020 and published figure upto 3rd quarter ended 31st December 2019.

Place : New Delhi
Date : 29 July, 2020



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director
DIN No 00059492

Jagsonpal Pharmaceuticals Limited
Cash Flow Statement for the year ended 31st.March 2020

Particulars	(In Rs. Lakhs)	
	31.03.2020	31.03.2019
A. Cash flow from operating activities		
Net Profit / (Loss) before extraordinary items and tax	941.48	900.28
Adjustments for:		
Depreciation and amortisation	112.98	101.58
(Profit) / loss on sale / write off of assets	1.60	-
Finance costs	51.41	74.55
Misc Income	(251.02)	(142.90)
Operating profit / (loss) before working capital changes	(i) 856.45	933.51
Changes in working capital:		
Adjustments for (increase) / decrease in operating assets:		
Inventories	(336.76)	(1,874.12)
Trade receivables	70.32	(440.34)
Other current assets	47.66	206.77
Other non-current assets	169.19	178.49
	(ii) 49.59	1,929.20
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	15.11	(276.78)
Other current liabilities	(255.59)	49.66
Other long-term liabilities	-	-
Short-term provisions	(135.33)	185.28
	(iii) (375.81)	(41.84)
	(ii)-(iii) 425.40	1,971.04
Cash flow from extraordinary items		
Cash generated from operations	(i)+(ii)-(iii) 1,281.85	2,904.55
Net income tax (paid) / refunds	(iv) (157.15)	185.28
Net cash flow from / (used in) operating activities (A)	(i) to (iv) 1,124.70	3,089.83
B. Cash flow from investing activities		
Capital expenditure on fixed assets	(v) -206.80	(225.49)
Proceeds from sale of fixed assets	(vi) 18.14	-
Investments	(vii) -1138.63	-
Misc Income	(viii) 251.02	142.90
Net cash flow from / (used in) investing activities (B)	(v) to (viii) (1,076.27)	(82.59)
C. Cash flow from financing activities		
Net increase / (decrease) in working capital borrowings	(ix) 55.14	(231.43)
Proceeds from other short-term borrowings	(x) 32.80	(220.08)
Repayment of other short-term borrowings	(xi) -	-
Finance cost	(xii) (51.41)	(74.55)
Dividends paid	(xiii) (131.00)	(65.50)
Tax on dividend	(xiv) -	(13.46)
Cash flow from financing items	(ix) to (xiv) (94.47)	(605.02)
Net cash flow from / (used in) financing activities (C)	(ix) to (xiv) (94.47)	(605.02)
Net increase / (decrease) in Cash and cash equivalents (A+B+C)	(46.04)	2,402.22
Cash and cash equivalents at the beginning of the year	3,853.46	1,451.24



Rana

Cash and cash equivalents at the end of the year		3,807.42	3,853.46
I.Components of cash and cash equivalents:			
Cash on hand		27.75	35.70
Balances with scheduled banks:			
On current accounts		499.30	722.30
On deposit accounts (deposits having original maturity of 12 months or less)		3,280.37	3,095.46
		3,807.42	3,853.46
Cash and cash equivalents as per note 10		3,807.42	3,853.46

II. The above cash flow statement has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard (Ind AS 7) - Statement cash Flows Specified under section 133 of the companies Act , 2013 read with Rule 7 of the Companies (Accounts) Rules , 2014.

II. Previous year's figures have been regrouped and /or rearranged wherever considered necessary to conform to current year's presentation.

In terms of our report attached
For H L Bansal and CO.
Chartered Accountants
FRN. NO. 008563N



Hira Lal Bansal
Partner
M.No. 086990
Place : New Delhi
Date : 29.07.2020

For and on behalf of the Board of Directors
For Jagsonpal Pharmaceuticals Limited

R.P.S Kochhar DIN 00059492
Chairman & Managing Director

S.K. Dudeja
Chief Financial Officer

Nandita Singh
Company Secretary